Skip to main content
Equibles
AMRX logo

AMRX · Amneal Pharmaceuticals, Inc.

Track AMRX — free

Use AMRX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$17.44 -0.43 (-2.41%) At close · Sep 4
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$5.57B
Shares
319.35M

AMRX metrics

86 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$17.44
Market cap
$5.57B

Price action

19 metrics
Price change (1W)
-0.6%
Price change (30D)
-3.5%
Price change (3M)
+26.8%
Price change (6M)
+31.7%
Price change (YTD)
+38.4%
Price change (1Y)
+82.6%
Trailing year
Price change (5Y)
+221.8%
52-week high
$19.10
52-week low
$9.55
Change from 52-week high
-8.7%
Change from 52-week low
+82.6%
Annualized volatility
33.6%
Beta
0.6
RSI (14D)
45.1
Price vs SMA 50
-1.8%
Price vs SMA 200
+21.3%
Avg volume (3M)
2.00M
Relative volume
0.7
Average dollar volume
$34.63M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
319.35M

Valuation

12 metrics
P / E (TTM)
36.3
Trailing earnings · reciprocal yield 2.8%
PEG ratio
0.2
EV / revenue
2.6×
reciprocal yield 38.9%
EV / EBITDA
—
EV / EBIT
17.7×
reciprocal yield 5.7%
P / sales
1.8×
reciprocal yield 56.0%
P / book
168.7
reciprocal yield 0.6%
FCF yield
2.3%
TTM · current market cap
Buyback yield
—
P / FCF
43.6
reciprocal yield 2.3%
P / operating cash flow
27.7
reciprocal yield 3.6%
Earnings yield
2.8%

Historical valuation

8 metrics
P / E historical average (3Y)
268.4×
reciprocal yield 0.4%
P / E historical average (5Y)
230.5×
reciprocal yield 0.4%
EV / revenue historical average (3Y)
1.9×
reciprocal yield 51.8%
EV / revenue historical average (5Y)
1.9×
reciprocal yield 51.8%
EV / EBIT historical average (3Y)
19.4×
reciprocal yield 5.1%
EV / EBIT historical average (5Y)
19.4×
reciprocal yield 5.1%
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
39.3%
Operating margin
14.6%
Trailing 12 months
Net margin
5.0%
Gross profit (TTM)
$1.23B
Operating profit (TTM)
$453.92M
Net income (TTM)
$157.36M
Trailing 12 months
Diluted EPS (TTM)
$0.48
FCF margin
4.1%
Effective tax rate
-7.0%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+9.9%
Year over year
Net income growth YoY
+157.2%
Revenue (TTM)
$3.12B
Trailing 12 months
EPS growth YoY
+157.1%
Shares change YoY
+1.8%
Year over year · more shares
Revenue CAGR (3Y)
+10.9%
Revenue CAGR (5Y)
+8.7%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
-18.5%
FCF CAGR (3Y)
+143.5%
FCF CAGR (5Y)
-3.5%

Quality

14 metrics
Return on equity
476.5%
Return on assets
4.2%
Debt / equity
77.8
Current ratio
2.2
EBITDA (TTM)
—
Free cash flow (TTM)
$127.83M
Quick ratio
1.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$2.44B
Latest balance sheet
Cash & equivalents
$127.64M
Total assets
$3.78B
Total debt
$2.57B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$200.78M
Capital expenditures (TTM)
$72.94M
R&D (TTM)
$175.57M
SG&A (TTM)
$571.86M
Stock compensation (TTM)
$35.63M
R&D / revenue
5.6%
Stock compensation / revenue
1.1%

Ownership (13F)

3 metrics
13F filers
312
13F filer change QoQ
-6
Institutional ownership
51.2%

Short interest

3 metrics
Short interest
3.0%
Latest settlement · 4.9 days to cover
Days to cover
4.9d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$7.22M
Insider-sentiment score
15 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1723128 CUSIP 03168L105 13F (30d) 211 filings 210 filers Visit website Investor relations